Episode 23013
One Company, Two Different Drugs - It's All About Glucose - Too Much and Too Little! Nevan Charles Elam, Founder & CEO, Rezolute
BioTech Nation ... with Dr. Moira Gunn · Moira Gunn
August 14, 202418m 52s
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Glucose is essential for life. And the insulin we produce is designed to leave just the right of amount in our bodies for healthy functioning. Thus, when we underproduce insulin - or we overproduce it - the results can be devastating. Nevan Charles Elam, Founder and CEO of Rezolute, tells us about their work to treat the “diabetic eye condition”, DME, and a pediatric condition called Congenital hyperinsulinism.
Topics
glucoseinsulinDMEbiotechpharmaceuticalstherpeuticsmoira gunnrezolutecongenital hyperinsulinismdiabetesnevan charles elam